We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$517M
$45.8M 0.88%
2,389,600
+3,000
+0.1% +$72.9K
GEHC icon
27
GE HealthCare
GEHC
$28.7B
$41M 0.79%
524,414
-7,553
-1% -$642K
EXAS
28
DELISTED
Exact Sciences
EXAS
$39M 0.75%
694,056
-755,409
-52% -$47M
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.23B
$38.2M 0.73%
1,428,929
– –
BEAM icon
30
Beam Therapeutics
BEAM
$2.74B
$37.6M 0.72%
1,518,121
– –
PRCT icon
31
Procept Biorobotics
PRCT
$1.09B
$37.3M 0.72%
462,894
-149,797
-24% -$12.8M
RMD icon
32
ResMed
RMD
$28.6B
$36.8M 0.71%
160,793
+665
+0.4% +$160K
IMCR icon
33
Immunocore
IMCR
$1.74B
$35.6M 0.68%
1,205,464
– –
LLY icon
34
Eli Lilly
LLY
$1.03T
$35.1M 0.68%
45,465
+1,219
+3% +$1.01M
CI icon
35
Cigna
CI
$75.1B
$34.6M 0.67%
125,205
+6,798
+6% +$2.17M
ALGN icon
36
Align Technology
ALGN
$12.6B
$33.4M 0.64%
160,003
+16,007
+11% +$3.58M
COO icon
37
Cooper Companies
COO
$14B
$32.8M 0.63%
357,130
-40,243
-10% -$4.1M
MGNX icon
38
MacroGenics
MGNX
$278M
$32.3M 0.62%
9,929,963
– –
IDXX icon
39
Idexx Laboratories
IDXX
$44.6B
$31.8M 0.61%
76,935
-14,344
-16% -$6.29M
TMO icon
40
Thermo Fisher Scientific
TMO
$197B
$31.7M 0.61%
60,962
+7,339
+14% +$4.03M
ZBH icon
41
Zimmer Biomet
ZBH
$17.4B
$31M 0.6%
293,621
-139,184
-32% -$14.9M
RLAY icon
42
Relay Therapeutics
RLAY
$4.23B
$30.4M 0.59%
7,377,292
+108
+0% +$588
GMED icon
43
Globus Medical
GMED
$10.4B
$30M 0.58%
362,979
-106,819
-23% -$8.42M
CDNA icon
44
CareDx
CDNA
$1.99B
$29.4M 0.57%
1,374,412
-1,771,044
-56% -$43.1M
TNDM icon
45
Tandem Diabetes Care
TNDM
$1.22B
$28.2M 0.54%
782,456
-1,068,435
-58% -$36.1M
DHR icon
46
Danaher
DHR
$143B
$27.5M 0.53%
119,922
+14,332
+14% +$3.52M
INSP icon
47
Inspire Medical Systems
INSP
$1.51B
$27.5M 0.53%
148,478
-46,602
-24% -$9.05M
VEEV icon
48
Veeva Systems
VEEV
$32.4B
$26.8M 0.52%
127,575
-35,937
-22% -$7.9M
ANNX icon
49
Annexon
ANNX
$922M
$26.5M 0.51%
5,157,290
– –
VRNA
50
DELISTED
Verona Pharma
VRNA
$26.4M 0.51%
568,955
-651,104
-53% -$24.4M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.